Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: evidence of cholinergic supersensitivity.
The growth hormone response to the acetylcholinesterase inhibitor pyridostigmine was measured in nine normothymic outpatients who met DSM-III-R criteria for obsessive-compulsive disorder. The responses were significantly elevated when compared to those found in a healthy comparison group (N = 9). The data suggest that cholinergic supersensitivity is present in obsessive-compulsive disorder.
Department of Psychiatry, Trinity College Medical School, St. James Hospital, Dublin, Ireland.
J V
JV
Lucey
G
G
Butcher
A W
AW
Clare
T G
TG
Dinan
D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D010275:Parasympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology; D011729:Pyridostigmine Bromide / Q000494:pharmacology; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology
D011950:Receptors, Cholinergic; D013006:Growth Hormone; D011729:Pyridostigmine Bromide